{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:37:09Z","timestamp":1787870229072,"version":"build-2784847793"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"California HIV Research Program","award":["EI11-LA-002"],"award-info":[{"award-number":["EI11-LA-002"]}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 MH080634"],"award-info":[{"award-number":["T32 MH080634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among a cohort of men who have sex with men in a pre-exposure prophylaxis (PrEP) adherence trial, syphilis requiring treatment was associated with white coat dosing (increased PrEP adherence immediately preceding study visits) when compared with participants with optimal drug concentrations. The findings highlight the need for identifying and reducing barriers to PrEP adherence.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa329","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T18:25:16Z","timestamp":1596824716000},"source":"Crossref","is-referenced-by-count":7,"title":["PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6535-0018","authenticated-orcid":false,"given":"Cher\u00ede S","family":"Blair","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Beymer","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Fielding School of Public Health at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M","family":"Kofron","sequence":"additional","affiliation":[{"name":"UCLA Center for Clinical AIDS Research & Education, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Bolan","sequence":"additional","affiliation":[{"name":"Department of Health and Mental Health Services, Los Angeles LGBT Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert C","family":"Jordan","sequence":"additional","affiliation":[{"name":"OASIS Clinic, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"Haubrich","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R","family":"Wohl","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J","family":"Landovitz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"UCLA Center for Clinical AIDS Research & Education, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"2020082113465284400_CIT0001","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"2020082113465284400_CIT0002","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2020082113465284400_CIT0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11904-018-0377-0","article-title":"Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring","volume":"15","author":"Castillo-Mancilla","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2020082113465284400_CIT0004","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archinte.1990.00390190043003","article-title":"On white-coat effects and the electronic monitoring of compliance","volume":"150","author":"Feinstein","year":"1990","journal-title":"Arch Intern Med"},{"key":"2020082113465284400_CIT0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1310\/hct0904-238","article-title":"\u201cWhite coat compliance\u201d limits the reliability of therapeutic drug monitoring in HIV-1-infected patients","volume":"9","author":"Podsadecki","year":"2008","journal-title":"HIV Clin Trials"},{"key":"2020082113465284400_CIT0006","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1128\/AAC.01017-16","article-title":"Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing","volume":"60","author":"Castillo-Mancilla","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082113465284400_CIT0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eclinm.2018.09.003","article-title":"What can urine tell us about medication adherence?","volume":"2\u20133","author":"Anderson","year":"2018","journal-title":"EClinicalMedicine"},{"key":"2020082113465284400_CIT0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0000000000001971","article-title":"Brief report: validation of a urine tenofovir immunoassay for adherence monitoring to PrEP and ART and establishing the cutoff for a point-of-care test","volume":"81","author":"Gandhi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020082113465284400_CIT0009","article-title":"Near-perfect accuracy of a real-time urine tenofovir test compared to lab-based ELISA","author":"Spinelli"},{"key":"2020082113465284400_CIT0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","article-title":"FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis","volume":"66","author":"Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020082113465284400_CIT0011","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/QAD.0000000000000801","article-title":"Disclosure of pharmacokinetic drug results to understand nonadherence","volume":"29","author":"van der Straten","year":"2015","journal-title":"AIDS"},{"key":"2020082113465284400_CIT0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0000000000002032","article-title":"A Comparison of plasma efavirenz and tenofovir, dried blood spot tenofovir-diphosphate, and self-reported adherence to predict virologic suppression among South African women","volume":"81","author":"Phillips","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020082113465284400_CIT0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/QAI.0000000000001538","article-title":"Plasma tenofovir levels to support adherence to TDF\/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California","volume":"76","author":"Landovitz","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020082113465284400_CIT0014","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2020082113465284400_CIT0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020082113465284400_CIT0016","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy368","article-title":"Trajectories and predictors of longitudinal preexposure prophylaxis adherence among men who have sex with men","volume":"218","author":"Pasipanodya","year":"2018","journal-title":"J Infect Dis"},{"key":"2020082113465284400_CIT0017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/QAI.0000000000002051","article-title":"Adherence to PrEP among young men who have sex with men participating in a sexual health services demonstration project in Alameda county, California","volume":"81","author":"Myers","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020082113465284400_CIT0018","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/09540121.2019.1595523","article-title":"Effective use of pre-exposure prophylaxis (PrEP) among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles","volume":"31","author":"Goodman-Meza","year":"2019","journal-title":"AIDS Care"},{"key":"2020082113465284400_CIT0019","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1007\/s10461-019-02502-y","article-title":"Barriers and facilitators of PrEP adherence for young men and transgender women of color","volume":"23","author":"Wood","year":"2019","journal-title":"AIDS Behav"},{"key":"2020082113465284400_CIT0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000209","article-title":"Should we fear resistance from tenofovir\/emtricitabine preexposure prophylaxis?","volume":"11","author":"Parikh","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2020082113465284400_CIT0021","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"key":"2020082113465284400_CIT0022","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1932296816672691","article-title":"White coat adherence occurs in adolescents with type 1 diabetes receiving intervention to improve insulin pump adherence behaviors","volume":"11","author":"Driscoll","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"2020082113465284400_CIT0023","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jpeds.2012.03.059","article-title":"White coat adherence over the first year of therapy in pediatric epilepsy","volume":"161","author":"Modi","year":"2012","journal-title":"J Pediatr"},{"key":"2020082113465284400_CIT0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/OLQ.0000000000000810","article-title":"Reported primary and secondary syphilis cases in the United States: implications for HIV infection","volume":"45","author":"Kidd","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2020082113465284400_CIT0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1089\/aid.2016.0202","article-title":"Differences in cumulative exposure and adherence to tenofovir in the VOICE, iPrEx OLE, and PrEP demo studies as determined via hair concentrations","volume":"33","author":"Koss","year":"2017","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa329\/33588506\/ofaa329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa329\/33672263\/ofaa329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa329\/33672263\/ofaa329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T17:47:07Z","timestamp":1598032027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa329\/5885070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa329","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,8,1]]},"article-number":"ofaa329"}}